Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palucorcel in Geographic Atrophy Secondary to AMD
NCT01226628Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2010
- Primary completion
- Mar 2015
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of palucorcel in geographic atrophy (GA) (8 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Number of eyes with serious ocular adverse events at 12 months. Started Oct 2010; status: completed.
02
Drugs
palucorcel
03
Conditions
geographic atrophy (GA)
Beyond the preview
Go deeper on NCT01226628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01226628.